Zhuvaka, K. S.
Volynets, G. P.
Ruban, T. P.
Nidoeva, Z. M.
Iatsyshyna, A. P.
Macewizc, L. L.
Bdzhola, V. G.
Yarmoluk, S. M.
Lukash, L. L.
Article History
Received: 1 July 2023
Revised: 3 August 2023
Accepted: 13 November 2023
First Online: 4 December 2023
Change Date: 31 January 2024
Change Type: Update
Change Details: Modifications have been made to the Publisher’s Note.
COMPLIANCE WITH ETHICAL STANDARDS
: The authors declare that they have no conflicts of interest. This article does not contain any studies involving animals or human participants performed by any of the authors.
: In this study we examined a number of compounds for their potential as MGMT inhibitors and assessed their cytotoxicity and effectiveness in vitro. Results indicated that compounds 41 (5-(5-Сhloro-2-hydroxy-benzylidene)-4-thioxo-thiazolidin-2-one), 41B (5-Benzo[1,3]dioxol-5-ylmethylene-thiazolidine-2,4-dione), and 89 (2-[5-(4-Bromo-phenyl)-pyrimidin-4-yl]-5-ethoxy-phenol) showed promising characteristics with lower cytotoxicity and higher effectiveness compared to the standard inhibitor BG at a concentration of 10 µM.